Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Comparative global B cell receptor repertoire difference induced by SARS-CoV-2 infection or vaccination via single-cell V(D)J sequencingSARS-CoV-2 감염 또는 단일 세포 V(D)J 시퀀싱을 통한 백신 접종에 의해 유도된 비교 글로벌 B 세포 수용체 레퍼토리 차이Article Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, [키워드] antibody B cell BBIBP-CorV BCR BCR repertoire change Comparative COVID-19 COVID-19 recovered patient dynamic FIVE group groups Guidance healthy healthy donor humoral immune response IGHV3-23 IGHV3-33 inactivated Inactivated vaccine Infection performed Precision proportion receptor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 vaccination SARS-CoV-2 vaccine Sequencing single-cell Single-cell RNA sequencing subject subjects the SARS-CoV-2 treated vaccination Vaccine [DOI] 10.1080/22221751.2022.2105261 PMC 바로가기 [Article Type] Article
B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses강력하고 불량한 SARS-CoV-2 백신 반응과 관련된 B 세포 수용체 신호Article Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, [키워드] age antibody Antibody Response B cell B cell receptor Biomarker class switch recombination clone Cohort COVID-19 healthy IgG IgM Immunity inactivated Inactivated vaccine individuals Infection molecular mRNA Neutralizing antibodies receptor recipient Reinfection response SARS-CoV-2 SARS-CoV-2 vaccine the antibody response vaccinated individual vaccination Vaccination strategies vaccine-induced antibody response [DOI] 10.1080/22221751.2022.2030197 PMC 바로가기 [Article Type] Article
Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variantsArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition adenoviral vector Adenovirus adenovirus type 5 vector vaccine Anti-RBD IgG booster COVID-19 COVID-19 vaccine D614G demonstrated dose effective Efficacy IgA immunization Inactivated vaccine Inactivated Vaccines Inhaled lack mucosal Neutralization assay Neutralizing neutralizing antibody omicron Omicron variant BA.5 pandemic plasma Protective RBD SARS-CoV-2 SARS-CoV-2 pseudovirus SARS-CoV-2 vaccines SARS-CoV-2 variant subunit titre Vaccination strategies Vaccination strategy Vaccine variant virus widespread [DOI] 10.1080/22221751.2022.2132881 PMC 바로가기
Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variantsArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Administered Antibody neutralization BBIBP-CorV Beta booster vaccination circulating CoronaVac coronavirus Delta Eta Gamma humoral immune response immune immune response inactivated Inactivated vaccine individual Lineage lineages morbidity and mortality Mutation neutralization neutralization titer neutralize neutralized Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody response omicron reduce SARS-CoV-2 SARS-CoV-2 variant second vaccination serum sample significantly lower the SARS-CoV-2 vaccine dose variant viral variant Viral variants virus virus strain viruses wild-type [DOI] 10.1002/jmv.28049 PMC 바로가기
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variantsCoronVac 백신 3차 접종은 SARS-CoV-2 Delta 및 Omicron 변이체를 인식하는 광범위하고 강력한 적응 면역 반응 유도Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immune response B cell B cells boost booster booster dose booster vaccination CD4 CD8 Cell circulating comparable contagious CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta demonstrated detectable domain dose effective elevated elicited fold follicular healthy subject helper T cell Humoral immunity IgA responses immune responses Inactivated vaccine individual induce memory B memory B cell memory B cells neutralization neutralization activities neutralization activity neutralizing activities omicron Omicron variants peaked predominant preserved Protein RBD receiving recognize reduced remained respiratory response SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 variant significantly increased spike-specific IgG strain subpopulations sustained T cell T cell responses T cells T cells response vaccination variant variants VOCs [DOI] 10.1080/22221751.2022.2081614 PMC 바로가기 [Article Type] Article
Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants코로나바이러스 질병 재조합 소단위 백신의 세 번째 용량으로 이종 부스팅은 다양한 중증 급성 호흡기 증후군 코로나바이러스 2 변이체에 대한 중화 항체 및 T 세포 면역을 증가시킵니다Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis Anti-RBD IgG anti-S booster vaccination CD4+ T cell components composite pattern coronavirus coronavirus disease COVID-19 COVID-19 vaccinations COVID-19 vaccine dose effective epitope Epitopes evaluated Evidence help Heterologous heterologous boosting homologous Humoral immunity Immune escape Immunity immunization strategy immunological in some inactivated Inactivated vaccine increase magnitude NAb NAbs natural infection Neutralizing Neutralizing antibodies neutralizing antibody neutralizing capacity omicron pandemic prime-boost strategy produced RBD IgG respiratory subunit Subunit vaccine T cell T cell response T cells titre vaccination Vaccination strategies Vaccination strategy Vaccine Vaccine-induced immunity variant variants of concern waned [DOI] 10.1080/22221751.2022.2048969 PMC 바로가기 [Article Type] Article
Distinct immune responses in the early phase to natural SARS-CoV-2 infection or vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, [키워드] acute phase acute respiratory syndrome analyzed antibody Antibody Response coronavirus cytokine cytokine expression cytokine level Cytokines dose early phase elicited expression healthy IgA antibody immune response immunization implication inactivated Inactivated vaccine Inactivated Vaccines infected individuals natural infection nucleocapsid postvaccination Protein Reinfection response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccine SARS-CoV-2 vaccines serological significant differences two groups vaccination Vaccines variety viral infection [DOI] 10.1002/jmv.28034 PMC 바로가기
Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection2003년 SARS-CoV 감염 이력이 있는 개인에서 비활성화된 SARS-CoV-2 백신 접종 후 광범위하고 지속적인 항체 반응Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] activity antibody Antibody Response Antigen Beta Delta dosage greater Heterologous heterologous immunization inactivated Inactivated vaccine individual naïve vaccinees neutralizing activities Neutralizing activity nucleoprotein omicron pseudovirus pseudoviruses RBD of SARS-CoV-2 receiving SARS-CoV SARS-CoV infection SARS-CoV-2 SARS-CoV-2 vaccine SARS-related coronaviruses second vaccination significantly higher suggested undetectable Universal vaccine vaccination Vaccine vaccinee vaccinees variant variants virus viruses were infected Wuhan [DOI] 10.1080/22221751.2022.2076613 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIVHIV 보균자에서 비활성화된 SARS-CoV-2 백신의 안전성 및 면역원성Observational Study Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] adverse event age Analysis binding domain booster dose CD4 CD4 count CD4 counts Cell COVID-19 declined Efficacy enrolled evaluated Factor Frequency Gender geometric GMT healthy control healthy controls HIV humoral humoral immune response IgG immune immune response Immunocompromised in both groups inactivated Inactivated vaccine less MBC memory B occurred Patient PLWH predicted prospective observational study reduced remained reported response responses robust Safety SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event Seven significantly vaccination Viral load with HIV [DOI] 10.1080/22221751.2022.2059401 PMC 바로가기 [Article Type] Observational Study